Global Neurodegenerative Diseases Drugs Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application

Report ID: ARS12563 | Category: Healthcare and Pharmaceuticals | Pages: 113 | Format: PDF | Published Date: December 18,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3350.00 Multi User-$5700.00

Report Description
View Table of Contents

Report Summary

This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Diseases Drugs, with and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Diseases Drugs.

The Neurodegenerative Diseases Drugs market size considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Neurodegenerative Diseases Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurodegenerative Diseases Drugs manufacturers, new entrants, and industry chain related companies in this market with information for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

The global Neurodegenerative Diseases Drugs market size in 2022 is 41730.0 million US dollars, and it is expected to be 67448.9 million US dollars by 2029, with a compound annual growth rate of 7.10% expected in 2023-2029.

MARKET COMPETITIVE LANDSCAPE:
The main players in the Neurodegenerative Diseases Drugs market include Pfizer, Inc., Merck KGaA, Novartis AG, Acadia Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd.. The share of the top 3 players in the Neurodegenerative Diseases Drugs market is XX%.

REGION SHARE:
The report covers the market size information of North America, Europe, Asia Pacific, Latin America, Middle East and Africa, and North America accounted for XX%, Europe accounted for XX% of Neurodegenerative Diseases Drugs market, and Asia Pacific accounted for XX%.

SEGMENT OVERVIEW:
The report segments the market by Type and Application. Oral accounted for XX% of Neurodegenerative Diseases Drugs market in 2022. Injection share of XX%.
Hospital Pharmacy accounted for XX% of the Neurodegenerative Diseases Drugs market in 2022. Retail Pharmacy accounts for XX%.

Chapter Outline
Chapter 1: Introduces the product overview, and global Neurodegenerative Diseases Drugs market status and forecast by region.
Chapters 2-3: Segmented the global Neurodegenerative Diseases Drugs market by type, and application. Analyze the revenue of market segments from different perspectives.
Chapter 4: Analysis of the competitive environment of Neurodegenerative Diseases Drugs market participants. This mainly includes the revenue and market share of the top players, along with the players' M&A and expansion in recent years.
Chapters 5-9: Provide North America, Europe, Asia-Pacific, Latin America and Middle East & Africa Neurodegenerative Diseases Drugs market country segmentation data.
Chapter 10: Analyzes the main companies in the Neurodegenerative Diseases Drugs industry, including their main businesses, products/services, revenue, gross margin, and the latest developments.
Chapter 11: Introduces the market dynamics, the trends factors and drivers factors of the market, and the challenges and restraints faced by manufacturers in the industry.
Chapter 12: The main points and conclusions of the report.
Chapter 13: Concludes with an explanation of the data sources and research methods.

Highlights-Regions

North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia Pacific
China
Japan
South Korea
India
Southeast Asia
South America
Brazil
Argentina
Colombia
MEA
Saudi Arabia
Egypt
Nigeria

Player list
Pfizer, Inc.
Merck KGaA
Novartis AG
Acadia Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd.
F. Hoffmann-La Roche Ltd

Types list
Oral
Injection
Transdermal

Application list
Hospital Pharmacy
Retail Pharmacy
Online

Table of Content

1 Neurodegenerative Diseases Drugs Market Overview
1.1 Neurodegenerative Diseases Drugs Product Overview
1.1.1 Neurodegenerative Diseases Drugs Product Scope
1.1.2 Neurodegenerative Diseases Drugs Market Status and Outlook
1.2 Global Neurodegenerative Diseases Drugs Market Size Overview by Region 2018 VS 2022VS 2029
1.3 Global Neurodegenerative Diseases Drugs Market Size by Region (2018-2029)
1.4 Global Neurodegenerative Diseases Drugs Historic Market Size by Region (2018-2023)
1.5 Global Neurodegenerative Diseases Drugs Market Size Forecast by Region (2023-2029)
1.6 Key Regions, Neurodegenerative Diseases Drugs Market Size (2018-2029)
1.6.1 North America Neurodegenerative Diseases Drugs Market Size (2018-2029)
1.6.2 Europe Neurodegenerative Diseases Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Neurodegenerative Diseases Drugs Market Size (2018-2029)
1.6.4 Latin America Neurodegenerative Diseases Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Neurodegenerative Diseases Drugs Market Size (2018-2029)
2 Neurodegenerative Diseases Drugs Market Overview by Type
2.3 Global Neurodegenerative Diseases Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.4 Global Neurodegenerative Diseases Drugs Historic Market Size by Type (2018-2023)
2.5 Global Neurodegenerative Diseases Drugs Forecasted Market Size by Type (2023-2029)
2.6 Key Regions Market Size Segment by Type (2018-2029)
2.6.1 North America Neurodegenerative Diseases Drugs Market Size Breakdown by Type (2018-2029)
2.6.2 Europe Neurodegenerative Diseases Drugs Market Size Breakdown by Type
2.6.3 Asia-Pacific Neurodegenerative Diseases Drugs Market Size Breakdown by Type
2.6.4 Latin America Neurodegenerative Diseases Drugs Market Size Breakdown by Type
2.6.5 Middle East and Africa Neurodegenerative Diseases Drugs Market Size Breakdown by Type
3 Neurodegenerative Diseases Drugs Market Overview by Application
3.3 Global Neurodegenerative Diseases Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.4 Global Neurodegenerative Diseases Drugs Historic Market Size by Application (2018-2023)
3.5 Global Neurodegenerative Diseases Drugs Forecasted Market Size by Application (2023-2029)
3.6 Key Regions Market Size Segment by Application (2018-2029)
3.6.1 North America Neurodegenerative Diseases Drugs Market Size Breakdown by Application (2018-2029)
3.6.2 Europe Neurodegenerative Diseases Drugs Market Size Breakdown by Application
3.6.3 Asia-Pacific Neurodegenerative Diseases Drugs Market Size Breakdown by Application
3.6.4 Latin America Neurodegenerative Diseases Drugs Market Size Breakdown by Application
3.6.5 Middle East and Africa Neurodegenerative Diseases Drugs Market Size Breakdown by Application
4 Neurodegenerative Diseases Drugs Competition Analysis by Players
4.1 Global Neurodegenerative Diseases Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Drugs as of 2022)
4.3 Date of Key Players Enter into Neurodegenerative Diseases Drugs Market
4.4 Global Top Players Neurodegenerative Diseases Drugs Headquarters and Area Served
4.5 Key Players Neurodegenerative Diseases Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Neurodegenerative Diseases Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 North America Neurodegenerative Diseases Drugs Market Segment by Country
5.1 North America Neurodegenerative Diseases Drugs Market Size by Country (2018-2029)
5.2 United States
5.3 Canada
6 Europe Neurodegenerative Diseases Drugs Market Segment by Country
6.1 Europe Neurodegenerative Diseases Drugs Market Size by Country (2018-2029)
6.2 Germany
6.3 France
6.4 U.K.
6.5 Italy
6.6 Russia
6.7 Nordic
6.8 Rest of Europe
7 Asia-Pacific Neurodegenerative Diseases Drugs Market Segment by Country
7.1 Asia-Pacific Neurodegenerative Diseases Drugs Market Size by Region (2018-2029)
7.2 China
7.3 Japan
7.4 South Korea
7.5 Southeast Asia
7.6 India
7.7 Australia
7.8 Rest of Asia-Pacific
8 Latin America Neurodegenerative Diseases Drugs Market Segment by Country
8.1 Latin America Neurodegenerative Diseases Drugs Market Size by Country (2018-2029)
8.2 Mexico
8.3 Brazil
8.4 Rest of Latin America
9 Middle East and Africa Neurodegenerative Diseases Drugs Market Segment by Country
9.1 Middle East & Africa Neurodegenerative Diseases Drugs Market Size by Country (2018-2029)
9.2 Turkey
9.3 Saudi Arabia
9.4 UAE
9.5 Rest of Middle East & Africa
10 Manufacturers Profiles
10.1  Pfizer, Inc.
10.1.1 Pfizer, Inc. Information
10.1.2 Business Overview
10.1.3 Pfizer, Inc. Neurodegenerative Diseases Drugs Revenue, Gross Margin
10.1.4 Neurodegenerative Diseases Drugs Products Offered
10.1.5 Pfizer, Inc. Recent Development
10.2  Merck KGaA
10.2.1 Merck KGaA Information
10.2.2 Business Overview
10.2.3 Merck KGaA Neurodegenerative Diseases Drugs Revenue, Gross Margin
10.2.4 Neurodegenerative Diseases Drugs Products Offered
10.2.5 Merck KGaA Recent Development
10.3  Novartis AG
10.3.1 Novartis AG Information
10.3.2 Business Overview
10.3.3 Novartis AG Neurodegenerative Diseases Drugs Revenue, Gross Margin
10.3.4 Neurodegenerative Diseases Drugs Products Offered
10.3.5 Novartis AG Recent Development
10.4  Acadia Pharmaceuticals Inc.
10.4.1 Acadia Pharmaceuticals Inc. Information
10.4.2 Business Overview
10.4.3 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Drugs Revenue, Gross Margin
10.4.4 Neurodegenerative Diseases Drugs Products Offered
10.4.5 Acadia Pharmaceuticals Inc. Recent Development
10.5  Teva Pharmaceutical Industries Ltd.
10.5.1 Teva Pharmaceutical Industries Ltd. Information
10.5.2 Business Overview
10.5.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Diseases Drugs Revenue, Gross Margin
10.5.4 Neurodegenerative Diseases Drugs Products Offered
10.5.5 Teva Pharmaceutical Industries Ltd. Recent Development
10.6  F. Hoffmann-La Roche Ltd
10.6.1 F. Hoffmann-La Roche Ltd Information
10.6.2 Business Overview
10.6.3 F. Hoffmann-La Roche Ltd Neurodegenerative Diseases Drugs Revenue, Gross Margin
10.6.4 Neurodegenerative Diseases Drugs Products Offered
10.6.5 F. Hoffmann-La Roche Ltd Recent Development
11 Neurodegenerative Diseases Drugs Market Dynamics
11.1 Neurodegenerative Diseases Drugs Industry Trends
11.2 Neurodegenerative Diseases Drugs Growth Drivers
11.3 Neurodegenerative Diseases Drugs Market Challenges
11.4 Neurodegenerative Diseases Drugs Market Restraints
12 Research Findings and Conclusion
13 Methodology and Data Source
13.1 A Methodology
13.1.1 Research Process
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 B Data Source
13.2.1 Legal Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Global Neurodegenerative Diseases Drugs Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?